Alphatec Target of Unusually Large Options Trading (NASDAQ:ATEC)

Alphatec Holdings, Inc. (NASDAQ:ATEC) was the target of some unusual options trading on Friday. Stock traders bought 2,902 call options on the company. This is an increase of 92% compared to the average daily volume of 1,511 call options.

Alphatec Trading Up 2.0 %

ATEC traded up $0.19 on Friday, hitting $9.46. 466,159 shares of the company were exchanged, compared to its average volume of 1,975,557. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec has a 12 month low of $4.88 and a 12 month high of $14.88. The firm has a fifty day simple moving average of $10.95 and a two-hundred day simple moving average of $8.70. The stock has a market capitalization of $1.36 billion, a PE ratio of -7.38 and a beta of 1.39.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Sell-side analysts expect that Alphatec will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on ATEC. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Tuesday, January 14th. Barclays lifted their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Finally, Piper Sandler boosted their price objective on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Alphatec presently has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Insider Activity at Alphatec

In other Alphatec news, COO Scott Lish sold 27,453 shares of the stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares in the company, valued at approximately $9,969,608.73. This trade represents a 3.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick Miles sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total value of $601,500.00. Following the completion of the transaction, the chief executive officer now owns 6,152,544 shares in the company, valued at $74,015,104.32. The trade was a 0.81 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 337,321 shares of company stock valued at $3,828,060. 22.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Alphatec

Hedge funds and other institutional investors have recently modified their holdings of the stock. PharVision Advisers LLC bought a new position in shares of Alphatec in the 4th quarter worth approximately $201,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Alphatec by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,643 shares of the medical technology company’s stock worth $2,062,000 after buying an additional 22,971 shares during the period. Western Standard LLC bought a new position in Alphatec in the 4th quarter valued at approximately $6,668,000. Soviero Asset Management LP bought a new position in Alphatec during the 4th quarter valued at about $918,000. Finally, Wexford Capital LP purchased a new stake in Alphatec during the 4th quarter valued at $95,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.